



US010566566B2

(12) **United States Patent**
Jeon et al.

(10) **Patent No.:** **US 10,566,566 B2**

(45) **Date of Patent:** **Feb. 18, 2020**

(54) **ORGANOMETALLIC COMPOUND,
ORGANIC LIGHT-EMITTING DEVICE
INCLUDING THE ORGANOMETALLIC
COMPOUND, AND DIAGNOSIS
COMPOSITION INCLUDING THE
ORGANOMETALLIC COMPOUND**

(71) Applicant: **SAMSUNG ELECTRONICS CO.,
LTD.**, Suwon-si, Gyeonggi-do (KR)

(72) Inventors: **Aram Jeon**, Suwon-si (KR); **Chul
Baik**, Suwon-si (KR); **Jungin Lee**,
Hwaseong-si (KR); **Hwayoung Cho**,
Hwaseong-si (KR); **Seokhwan Hong**,
Seoul (KR); **Kyuyoung Hwang**,
Anyang-si (KR); **Ohyun Kwon**, Seoul
(KR); **Yoonhyun Kwak**, Seoul (KR)

(73) Assignee: **SAMSUNG ELECTRONICS CO.,
LTD.**, Gyeonggi-Do (KR)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 365 days.

(21) Appl. No.: **15/487,820**

(22) Filed: **Apr. 14, 2017**

(65) **Prior Publication Data**

US 2018/0090707 A1 Mar. 29, 2018

(30) **Foreign Application Priority Data**

Sep. 27, 2016 (KR) 10-2016-0124238

(51) **Int. Cl.**
H01L 51/50 (2006.01)
H01L 51/52 (2006.01)

(Continued)

(52) **U.S. Cl.**
CPC **H01L 51/5203** (2013.01); **C07F 15/0086**
(2013.01); **C09K 11/025** (2013.01);
(Continued)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,442,797 B2 10/2008 Itoh et al.
7,939,669 B2 5/2011 Suh et al.

(Continued)

FOREIGN PATENT DOCUMENTS

JP 2010-135689 A 6/2010
WO 2005-042444 A2 5/2005
WO 2007-078182 A1 7/2007


Primary Examiner — Gregory D Clark

(74) *Attorney, Agent, or Firm* — Cantor Colburn LLP

(57) **ABSTRACT**


An organometallic compound represented by Formula 1:

Formula 1



wherein, in Formula 1, groups and variables are the same
as described in the specification.

20 Claims, 1 Drawing Sheet



(51) **Int. Cl.**

C07F 15/00 (2006.01)
C09K 11/02 (2006.01)
C09K 11/06 (2006.01)
H01L 51/00 (2006.01)

(52) **U.S. Cl.**


CPC *C09K 11/06* (2013.01); *H01L 51/0072*
(2013.01); *H01L 51/0087* (2013.01); *H01L*
51/0094 (2013.01); *C09K 2211/1007*
(2013.01); *C09K 2211/1011* (2013.01); *C09K*
2211/1014 (2013.01); *C09K 2211/1022*
(2013.01); *C09K 2211/1029* (2013.01); *C09K*
2211/185 (2013.01); *H01L 51/5016* (2013.01);
H01L 51/5056 (2013.01); *H01L 51/5072*
(2013.01); *H01L 51/5088* (2013.01); *H01L*
51/5092 (2013.01); *H01L 51/5096* (2013.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

2013/0274473 A1 10/2013 Che et al.
2015/0194616 A1* 7/2015 Li H01L 51/0087
546/4

* cited by examiner



1

**ORGANOMETALLIC COMPOUND,
ORGANIC LIGHT-EMITTING DEVICE
INCLUDING THE ORGANOMETALLIC
COMPOUND, AND DIAGNOSIS
COMPOSITION INCLUDING THE
ORGANOMETALLIC COMPOUND**

**CROSS-REFERENCE TO RELATED
APPLICATION**

This application claims priority to Korean Patent Application No. 10-2016-0124238, filed on Sep. 27, 2016, in the Korean Intellectual Property Office, and all the benefits accruing therefrom under 35 U.S.C. § 119, the content of which is incorporated herein in its entirety by reference.

BACKGROUND

1. Field

One or more embodiments relate to an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnosis composition including the organometallic compound.

2. Description of the Related Art

Organic light-emitting devices (OLEDs) are self-emission devices that produce full-color images, and also have improved characteristics in terms of viewing angles, response time, luminance, driving voltage, and response speed.

In an example, an organic light-emitting device includes an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer includes an emission layer. A hole transport region may be disposed between the anode and the emission layer, and an electron transport region may be disposed between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and the electrons recombine in the emission layer to produce excitons. These excitons transition from an excited state to a ground state, thereby generating light.

Meanwhile, luminescent compounds may be used to monitor, sense, or detect a biological material such as a cell protein. Examples of such luminescent compounds include a phosphorescent luminescent compound.

Various types of organic light emitting devices are known. However, there still remains a need in OLEDs having low driving voltage, high efficiency, high brightness, and long lifespan.

SUMMARY


One or more embodiments include a novel organometallic compound, an organic light-emitting device including the novel organometallic compound, and a diagnosis composition including the novel organometallic compound.

Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

2

According to one or more embodiments, an organometallic compound is represented by Formula 1:

Formula 1



wherein, in Formula 1,

M may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au),

X₁ may be N and a bond between X₁ and M may be a covalent bond,

X₂ to X₄ may each independently be N or C, at least one of X₂ to X₄ may be C, one bond selected from a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M may be a covalent bond, and the remaining two bonds may each be a coordinate bond,

Y₁ to Y₉ may each independently be C or N, a bond between Y₁ and Y₂, a bond between Y₁ and Y₃, a bond between X₂ and Y₄, a bond between X₂ and Y₅, a bond between X₃ and Y₆, a bond between X₃ and Y₇, a bond between X₄ and Y₈, a bond between X₄ and Y₉, a bond between Y₂ and X₅₂, and a bond between X₅₁ and X₅₂ may each independently be a single bond or a double bond,

CY₁ to CY₅ may each independently be selected from a C₅-C₃₀ carbocyclic group and a C₁-C₃₀ heterocyclic group, a cyclometallated ring formed by CY₅, CY₁, CY₂, and M may be a 6-membered ring, a 7-membered ring, or an 8-membered ring,

T₁ to T₃ may each independently be selected from *—O—*, *—S—*, *—C(R₅)(R₆)—, *—C(R₅)=*, *—(R₅)=*, *—C(R₅)=C(R₆)—, *—C(=O)—, *—C(=S)—, *—C≡C—, *—N(R₅)—, *—Si(R₅)(R₆)—, and *—P(R₅)(R₆)—,

R₅ and R₆ may optionally be linked via a first linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

b₁ to b₃ may each independently be 0, 1, 2, or 3, wherein when b₁ is zero, *(T₁)_{b1}-* may be a single bond, when b₂ is zero, *(T₂)_{b2}-* may be a single bond, and when b₃ is zero, *(T₃)_{b3}-* may be a single bond,

X₅₁ may be selected from O, S, N, N(R₅₁), C(R₅₁), C(R₅₁)(R₅₂), Si(R₅₁)(R₅₂), and C(=O),

X₅₂ may be selected from O, S, N, N(R₅₃), C(R₅₃), C(R₅₃)(R₅₄), Si(R₅₃)(R₅₄), and C(=O),

R₅₁ and R₅₂ may optionally be linked via a second linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

R₅₃ and R₅₄ may optionally be linked via a third linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

R₅₁ and R₅₃ may optionally be linked via a fourth linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

R₁ to R₆ and R₅₁ to R₅₄ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, —SF₅, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀ alkyl group, a substituted or unsubstituted C₂-C₆₀ alkenyl group, a substituted or unsubstituted C₂-C₆₀ alkynyl group, a substituted or unsubstituted C₁-C₆₀ alkoxy group, a substituted or unsubstituted C₃-C₁₀ cycloalkyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀ cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀ aryl group, a substituted or unsubstituted C₆-C₆₀ aryloxy group, a substituted or unsubstituted C₆-C₆₀ arylthio group, a substituted or unsubstituted C₁-C₆₀ heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉),

a1 to a4 may each independently be 0, 1, 2, 3, 4, or 5,

two of groups R₁ in the number of a1 may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

two of groups R₂ in the number of a2 may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

two of groups R₃ in the number of a3 may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

two of groups R₄ in the number of a4 may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

two or more neighboring groups selected from R₁ to R₄ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

* and *' each indicate a binding site to a neighboring atom, and

at least one substituent of the substituted C₅-C₃₀ carbocyclic group, the substituted C₁-C₃₀ heterocyclic group, the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₁-C₆₀ heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group;

a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(=O)(Q₁₈)(Q₁₉);

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(=O)(Q₂₈)(Q₂₉); and

—N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(=O)(Q₃₈)(Q₃₉),

wherein Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one of a C₁-C₆₀ alkyl group and a

C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

According to one or more embodiments, an organic light-emitting device includes:

- a first electrode;
- a second electrode; and

an organic layer disposed between the first electrode and the second electrode, wherein the organic layer includes an emission layer and at least one organometallic compound.

The organometallic compound may act as a dopant in the emission layer.

According to one or more embodiments, a diagnosis composition includes at least one organometallic compound represented by Formula 1.

BRIEF DESCRIPTION OF THE DRAWING

These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with FIG. 1, which is a schematic view of an organic light-emitting device according to an embodiment.

DETAILED DESCRIPTION

Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects of the present disclosure. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

It will be understood that when an element is referred to as being “on” another element, it can be directly in contact with the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present.

It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

The term “or” means “and/or.” It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do


not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.

Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this general inventive concept belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.

“About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within $\pm 30\%$, 20% , 10% , 5% of the stated value.

An organometallic compound according to an embodiment may be represented by Formula 1 below:



wherein M in Formula 1 may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au).

In one or more embodiments, M in Formula 1 may be platinum (Pt), but embodiments of the present disclosure are not limited thereto.

The organometallic compound represented by Formula 1 may be a neutral compound which does not consist of an ion pair of a cation and an anion.

X₁ in Formula 1 may be N and a bond between X₁ and M may be a covalent bond.

X₂ to X₄ may each independently be N or C, one of X₂ to X₄ may be C, one bond selected from a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M may be a covalent bond, and the remaining two bonds may each be a coordinate bond.

In one or more embodiments, in Formula 1,

X₂ may be C, X₃ and X₄ may be N, a bond between X₂ and M may be a covalent bond, and a bond X₃ and M and a bond between X₄ and M may be a coordinate bond;

X₃ may be C, X₂ and X₄ may be N, a bond between X₃ and M may be a covalent bond, and a bond between X₂ and M and a bond between X₄ and M may be a coordinate bond; or

X₄ may be C, X₂ and X₃ may be N, a bond between X₄ and M may be a covalent bond, and a bond between X₂ and M and a bond between X₃ and M may be a coordinate bond, but embodiments of the present disclosure are not limited thereto.

In Formula 1,

Y₁ to Y₉ may each independently be C or N, and

a bond between Y₁ and Y₂, a bond between Y₁ and Y₃, a bond between X₂ and Y₄, a bond between X₂ and Y₅, a bond between X₃ and Y₆, a bond between X₃ and Y₇, a bond between X₄ and Y₈, a bond between X₄ and Y₉, a bond between Y₂ and X₅₂, and a bond between X₅₁ and X₅₂ may each independently be a single bond or a double bond.

In one or more embodiments, Y₁ to Y₉ in Formula 1 may be C, but embodiments of the present disclosure are not limited thereto.

CY₁ to CY₅ in Formula 1 may each independently be selected from a C₅-C₃₀ carbocyclic group and a C₁-C₃₀ heterocyclic group.

In one or more embodiments, in Formula 1,

CY₁, CY₂, and CY₄ may each independently be a 6-membered cyclic group,

CY₃ may be selected from a 6-membered cyclic group, a fluorene group, a carbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, and an azadibenzosilole group, and

CY₅ may be a 5-membered ring.

In one or more embodiments, CY₁ to CY₄ in Formula 1 may each independently be selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a

benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group.

In one or more embodiments, CY₁ to CY₄ in Formula 1 may each independently be selected from a benzene group, a naphthalene group, a fluorene group, a carbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a 1,2,3,4-tetrahydronaphthalene group, a pyridine group, a pyrimidine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group.

In one or more embodiments, in Formula 1,

CY₁ and CY₃ may each independently be selected from a benzene group, a naphthalene group, a fluorene group, a carbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, and a 1,2,3,4-tetrahydronaphthalene group, and

CY₂ and CY₄ may each independently be selected from a pyridine group, a pyrimidine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group, but embodiments of the present disclosure are not limited thereto.

A cyclometallated ring formed by CY₅, CY₁, CY₂, and M in Formula 1 may be a 6-membered ring, a 7-membered ring, or an 8-membered ring.

In one or more embodiments, a cyclometallated ring formed by CY₅, CY₁, CY₂, and M in Formula 1 may be a 6-membered ring, but embodiments of the present disclosure are not limited thereto.

T₁ to T₃ in Formula 1 may each independently be selected from *—O—*, *—S—*, *—C(R₅)(R₆)—*, *—C(R₅)=*, *—C(R₅)—*, *—C(R₅)=C(R₆)—*, *—C(=O)—*, *—C(=S)—*, *—C≡C—*, *—N(R₅)—*, *—Si(R₅)(R₆)—*, and *—P(R₅)(R₆)—*. R₅ and R₆ are the same as described below. * and *' each indicate a binding site to a neighboring atom.

R₅ and R₆ may optionally be linked via a first linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group.

In one or more embodiments, T₁ to T₃ in Formula 1 may each independently be selected from *—O—*, *—S—*, *—C(R₅)(R₆)—*, *—N(R₅)—*, *—Si(R₅)(R₆)—*, and *—P(R₅)(R₆)—*.

In one or more embodiments, T₁ to T₃ may each independently be selected from *—C(R₅)(R₆)—*, *—Si(R₅)(R₆)—*, and *—P(R₅)(R₆)—*.

R₅ and R₆ may be linked via a first linking group, the first linking group may be selected from a single bond, *—O—*, *—S—*, *—C(R₉)(R₁₀)—*, *—C(R₉)=*, *—C(R₉)—*, *—C(R₉)=C(R₁₀)—*, *—C(=O)—*, *—C(=S)—*, *—C≡C—*, *—N(R₉)—*, *—Si(R₉)(R₁₀)—*, and *—P(R₉)(R₁₀)—*, and

R₉ and R₁₀ are the same as described above in connection with R₅, and * and *' each indicate a binding site to a neighboring atom, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, T₁ to T₃ in Formula 1 may each be *—N(R₅)—*, but embodiments of the present disclosure are not limited thereto.

b1, b2, and b3 in Formula 1 respectively indicate the number of groups T₁, the number of groups T₂, and the

number of groups T_3 and may each independently be 0, 1, 2, or 3. When b_1 is zero, $*(T_1)_{b_1}-*$ may be a single bond, when b_2 is zero, $*(T_2)_{b_2}-*$ may be a single bond, and when b_3 is zero, $*(T_3)_{b_3}-*$ may be a single bond.

For example, b_1 to b_3 may each independently be 0 or 1.

In one or more embodiments, the sum of b_1 , b_2 , and b_3 in Formula 1 may be one or more. That is, at least one of $*(T_1)_{b_1}-*$, $*(T_2)_{b_2}-*$, and $*(T_3)_{b_3}-*$ in Formula 1 may not be a single bond.

In one or more embodiments, the sum of b_1 , b_2 , and b_3 in Formula 1 may be one or two. For example, the sum of b_1 , b_2 , and b_3 in Formula 1 may be one, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, in Formula 1,

b_1 may be one, and b_2 and b_3 may each be zero;

b_2 may be one, and b_1 and b_3 may each be zero; or

b_3 may be one, and b_1 and b_2 may each be zero, but embodiments of the present disclosure are not limited thereto.

X_{51} in Formula 1 may be selected from O, S, N, $N(R_{51})$, $C(R_{51})$, $C(R_{51})(R_{52})$, $Si(R_{51})(R_{52})$, and $C(=O)$, and X_{52} may be selected from O, S, N, $N(R_{53})$, $C(R_{53})$, $C(R_{53})(R_{54})$, $Si(R_{53})(R_{54})$, and $C(=O)$. R_{51} to R_{54} are the same as described above.

R_{51} and R_{52} may optionally be linked via a second linking group to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group,

R_{53} and R_{54} may optionally be linked via a third linking group to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group, and

R_{51} and R_{53} may optionally be linked via a fourth linking group to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group.

The first linking group, the second linking group, the third linking group, and the fourth linking group may each independently be selected from a single bond, $*-O-*$, $*-S-*$, $*-C(R_9)(R_{10})-*$, $*-C(R_9)=*$, $*-C(R_9)-*$, $*-C(R_9)=C(R_{10})-*$, $*-C(=O)-*$, $*-C(=S)-*$, $*-C\equiv C-*$, $*-N(R_9)-*$, $*-Si(R_9)(R_{10})-$, and $*-P(R_9)(R_{10})-*$, wherein R_9 and R_{10} are the same as described above.

CY_5 in Formula 1 may be a 5-membered ring including X_{51} and X_{52} .

In one or more embodiments, a bond between X_{51} and X_{52} in Formula 1 may be a double bond.

In one or more embodiments, X_{51} in Formula 1 may be selected from N, $N(R_{51})$, and $C(R_{51})$, and X_{52} may be selected from N, $N(R_{53})$, and $C(R_{53})$, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, in Formula 1,

X_{51} may be N and X_{52} may be $C(R_{53})$;

X_{51} may be $C(R_{51})$ and X_{52} may be N; or

X_{51} may be $C(R_{51})$ and X_{52} may be $C(R_{53})$, but embodiments of the present disclosure are not limited thereto.

R_1 to R_6 and R_{51} to R_{54} in Formula 1 may each independently be selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-SF_5$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1-C_{60} alkyl group, a substituted or unsubstituted C_2-C_{60} alkenyl group, a substituted or unsubstituted C_2-C_{60} alkynyl group, a substituted or unsubstituted C_1-C_{60} alkoxy group, a substituted or unsubstituted

substituted C_3-C_{10} cycloalkyl group, a substituted or unsubstituted C_1-C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3-C_{10} cycloalkenyl group, a substituted or unsubstituted C_1-C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6-C_{60} aryl group, a substituted or unsubstituted C_6-C_{60} aryloxy group, a substituted or unsubstituted C_6-C_{60} arylthio group, a substituted or unsubstituted C_1-C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-N(Q_1)(Q_2)$, $-Si(Q_3)(Q_4)(Q_5)$, $-B(Q_6)(Q_7)$, and $-P(=O)(Q_8)(Q_9)$. Q_1 to Q_9 are the same as described above.

For example, R_1 to R_6 and R_{51} to R_{54} in Formula 1 may each independently be selected from:

hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, $-SF_5$, a C_1-C_{20} alkyl group, and a C_1-C_{20} alkoxy group;

a C_1-C_{20} alkyl group and a C_1-C_{20} alkoxy group, each substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-CD_3$, $-CD_2H$, $-CDH_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1-C_{10} alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl (adamantyl) group, a norbornanyl (norbornyl) group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuran group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuran group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an

oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranlyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranlyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranlyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranlyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group; and —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉).

wherein Q₁ to Q₉ may each independently be selected from:

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCH₂H, —CHDCHD₂, —CHDCH₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.

In one or more embodiments, R₁ to R₆ and R₅₁ to R₅₄ in Formula 1 may each independently be selected from:

hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an

iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a carbazolyl group, a quinolinyl group, an isoquinolinyl group, a dibenzofuranlyl group, and a dibenzothiophenyl group;

a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a carbazolyl group, a quinolinyl group, an isoquinolinyl group, a dibenzofuranlyl group, and a dibenzothiophenyl group, each substituted with at least one selected from deuterium, —F, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a cyano group, a nitro group, a C₁-C₁₀ alkyl group, a C₁-C₁₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a carbazolyl group, a quinolinyl group, an isoquinolinyl group, a dibenzofuranlyl group, and a dibenzothiophenyl group; and

—N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉).

wherein Q₁ to Q₉ may each independently be selected from:

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCH₂H, —CHDCHD₂, —CHDCH₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;


an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.

In one or more embodiments, R₁ to R₆ and R₅₁ to R₅₄ in Formula 1 may each independently be selected from hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅,


13

—CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-48, and —Si (Q₃)(Q₄)(Q₅), but embodiments of the present disclosure are not limited thereto:














14

-continued



15

-continued

**16**

-continued

10-11

5

10-12

10

10-13

15

10-14

20

10-15

25

10-16

30

10-17

35

10-18

40

45

10-19

50











10-20

55

10-21

60

65



10-22

10-23

10-24

10-25

10-26

10-27

10-28









10-29

10-30

10-31

17


-continued

**18**

-continued


10-32

5




10-33

10




10-34

20




10-35

30




10-36

35




10-37

45




10-38

50



10-39

60



65

10-40

10-41

10-42

10-43

10-44


10-45

10-46

10-47

19

-continued



wherein * in Formulae 9-1 to 9-19 and 10-1 to 10-48 indicates a binding site to a neighboring atom. Q₃ to Q₅ are the same as described above.

a₁, a₂, a₃, and a₄ in Formula 1 respectively indicate the number of groups R₁, the number of groups R₂, the number of groups R₃, and the number of groups R₄, and may each independently be 0, 1, 2, 3, 4, or 5. When a₁ is two or more, two or more groups R₁ may be identical to or different from each other, when a₂ is two or more, two or more groups R₂ may be identical to or different from each other, when a₃ is two or more, two or more groups R₃ may be identical to or different from each other, and when a₄ is two or more, two or more groups R₄ may be identical to or different from each other, but embodiments of the present disclosure are not limited thereto.

Two of groups R₁ in the number of a₁ in Formula 1 may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, two of groups R₂ in the number of a₂ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, two of groups R₃ in the number of a₃ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, two of groups R₄ in the number of a₄ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, and two or more neighboring groups selected from R₁ to R₄ may optionally be selected from a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group.

For example, a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, which may be formed by optionally linking two of groups R₁ in the number of a₁, two of groups R₂ in the number of a₂, two of groups R₃ in the number of a₃, two of groups R₄ in the number of a₄, or two or more neighboring groups selected from R₁ to R₄ in Formula 1, may be selected from:

a pentadiene group, a cyclohexane group, an adamantane group, a bicyclo[2.2.1]heptane group, a benzene group, a furan group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a pyrrole group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, and an indole group; and

a pentadiene group, a cyclohexane group, an adamantane group, a bicyclo[2.2.1]heptane group, a benzene group, a furan group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a pyrrole group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, and an indole group, each substituted with

10-48


20

at least one R_{1a}, but embodiments of the present disclosure are not limited thereto.

R_{1a} is the same as described above in connection with R₁.


“An azabenzothiophene, an azabenzofuran, an azaindene, an azaindole, an azabenzosilole, an azadibenzothiophene, an azadibenzofuran, an azafluorene, an azacarbazole, and an azadibenzosilole” as described herein may mean hetero rings that respectively have the same backbones as “a benzothiophene, a benzofuran, an indene, an indole, an azabenzosilole, a dibenzothiophene, a dibenzofuran, a fluorene, a carbazole, and a dibenzosilole”, in which at least one carbon atom forming a ring thereof is substituted with nitrogen.

In one or more embodiments, a moiety represented by in



Formula 1 may be a group represented by Formula CY1-1:

CY1-1



wherein, in Formula CY1-1,

X₅₁ and X₅₂ are the same as described above,


X₁₁ may be N or C(R₁₁), X₁₂ may be N or C(R₁₂), and X₁₃ may be N or C(R₁₃),

R₁₁ to R₁₃ are each independently the same as described above in connection with R₁, and

* and *' each indicate a binding site to a neighboring atom.


For example, in Formula CY1-1, X₁₁ may be C(R₁₁), X₁₂ may be C(R₁₂), and X₁₃ may be C(R₁₃), but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, a moiety represented by








in Formula 1 may be selected from groups represented by Formulae CY2-1 to CY2-6:

CY2-1



21

-continued



wherein, in Formulae CY2-1 to CY2-6,


X_{21} may be N or C(R_{21}), X_{22} may be N or C(R_{22}), X_{23} may be N or C(R_{23}), X_{24} may be N or C(R_{24}), X_{25} may be N or C(R_{25}), X_{26} may be N or C(R_{26}), and X_{27} may be N or C(R_{27}),

R_{21} to R_{27} are each independently the same as described above in connection with R_2 , and

*, *', and *'' each indicate a binding site to a neighboring atom.

For example, in Formulae CY2-1 to CY2-6, X_{21} may be C(R_{21}), X_{22} may be C(R_{22}), X_{23} may be C(R_{23}), X_{24} may be C(R_{24}), X_{25} may be C(R_{25}), X_{26} may be C(R_{26}), and X_{27} may be C(R_{27}), but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, a moiety represented by




22

in Formula 1 may be selected from groups represented by Formulae CY3-1 to CY3-22:

CY2-2

5


CY3-1



CY2-3

10


CY3-2



CY2-4

20


CY3-3



CY2-5

25


CY3-4



CY2-6


30

CY3-5




35

CY3-6



40

CY3-7



45

50








55

60

65

23


-continued

**24**

-continued

CY3-8


5



10

CY3-9


15



20


CY3-10

25



CY3-11

30




35

40


CY3-12

45



CY3-13


50



55

CY3-14

60



65

CY3-15

CY3-16

CY3-17

CY3-18


CY3-19

CY3-20

CY3-21

25

-continued



wherein, in Formulae CY3-1 to CY3-22,

X_{31} may be N or C(R_{31}), X_{32} may be N or C(R_{32}), X_{33} may be N or C(R_{33}), X_{34} may be N or C(R_{34}), X_{35} may be N or C(R_{35}), X_{36} may be N or C(R_{36}), and X_{37} may be N or C(R_{37}).


X_{39} may be C(R_{39a})(R_{39b}) N(R_{39}), O, S, or Si(R_{39a})(R_{39b}),

R_{31} to R_{39} , R_{39a} , and R_{39b} are each independently the same as described above in connection with R_3 , and




*, *, and * each indicate a binding site to a neighboring atom.

For example, in Formulae CY3-1 to CY3-22, X_{31} may be C(R_{31}), X_{32} may be C(R_{32}), X_{33} may be C(R_{33}), X_{34} may be C(R_{34}), X_{35} may be C(R_{35}), X_{36} may be C(R_{36}), and X_{37} may be C(R_{37}), but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, a moiety represented by



in Formula 1 may be selected from groups represented by Formulae CY4-1 to CY4-8:




26

-continued


CY3-22

5


10




CY4-4




CY4-5



CY4-6



CY4-7



CY4-8

CY4-1

50

CY4-2

wherein, in Formulae CY4-1 to CY4-8,

X_{41} may be N or C(R_{41}), X_{42} may be N or C(R_{42}), X_{43} may be N or C(R_{43}), X_{44} may be N or C(R_{44}), X_{45} may be N or C(R_{45}), X_{46} may be N or C(R_{46}), X_{47} may be N or C(R_{47}), and X_{48} may be N or C(R_{48}),


CY4-3

R_{41} to R_{48} are each independently the same as described above in connection with R_4 , and


* and * each indicate a binding site to a neighboring atom.

For example, in Formulae CY4-1 to CY4-8, X_{41} may be C(R_{41}), X_{42} may be C(R_{42}), X_{43} may be C(R_{43}), X_{44} may be C(R_{44}), X_{45} may be C(R_{45}), X_{46} may be C(R_{46}), X_{47} may be C(R_{47}), and X_{48} may be C(R_{48}), but embodiments of the present disclosure are not limited thereto.


For example, in Formula 1,
a moiety represented by




may be a group represented by Formula CY1-1,
a moiety represented by



may be a group represented by Formula CY2-1,
a moiety represented by




may be selected from groups represented by Formulae
CY3-1 and CY3-8 to CY3-11, and
a moiety represented by



may be a group represented by Formula CY4-1, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, the organometallic compound may be represented by Formula 1-1:



wherein, in Formula 1-1,

M, T₁ to T₃, b1 to b3, X₅₁, and X₅₂ are the same as described above.

X_{11} may be N or C(R_{11}), X_{12} may be N or C(R_{12}), X_{13} may be N or C(R_{13}), X_{21} may be N or C(R_{21}), X_{22} may be N or C(R_{22}), X_{23} may be N or C(R_{23}), X_{31} may be N or C(R_{31}), X_{32} may be N or C(R_{32}), X_{33} may be N or C(R_{33}), X_{41} may be N or C(R_{41}), X_{42} may be N or C(R_{42}), X_{43} may be N or C(R_{43}), and X_{44} may be N or C(R_{44}).

¹⁰ R₁₁ to R₁₃ are each independently the same as described above in connection with R₁, and two of R₁₁ to R₁₃ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group.

R₂₁ to R₂₃ are each independently the same as described above in connection with R₂, and two of R₂₁ to R₂₃ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group.

R₃₁ to R₃₃ are each independently the same as described above in connection with R₃, and two of R₃₁ to R₃₃ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group.

R₄₁ to R₄₄ are each independently the same as described above in connection with R₄, and two of R₄₁ to R₄₄ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, and

two of R₁₁ to R₁₃, R₂₁ to R₂₃, R₃₁ to R₃₃, and R₄₁ to R₄₄ may optionally be linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group.

35 For example, in Formula 1-1,
 X_{11} may be $C(R_{11})$, X_{12} may be $C(R_{12})$, X_{13} may be
 $C(R_{13})$, X_{21} may be $C(R_{21})$, X_{22} may be $C(R_{22})$, X_{23} may be
 $C(R_{23})$, X_{31} may be $C(R_{31})$, X_{32} may be $C(R_{32})$, X_{33} may be
 $C(R_{33})$, X_{41} may be $C(R_{41})$, X_{42} may be $C(R_{42})$, X_{43} may be
40 $C(R_{43})$, and X_{44} may be $C(R_{44})$, and

R₁₁ to R₁₃, R₂₁ to R₂₃, R₃₁ to R₃₃, and R₄₁ to R₄₄ may each independently be selected from hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅, —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-48, and —Si(Q₃)(Q₄)(Q₅), but embodiments of the present disclosure are not limited thereto.

For example, a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, which may be formed by optionally linking two of R₁₁ to R₁₃, two of R₂₁ to R₂₃, two of R₃₁ to R₃₃, two of R₄₁ to R₄₄; or two of R₁₁ to R₁₃, R₂₁ to R₂₃, R₃₁ to R₃₃, and R₄₁ to R₄₄ in Formula 1-1, may be selected from:

a pentadiene group, a cyclohexane group, an adamantane
55 group, a bicyclo[2.2.1]heptane group, a benzene group, a
pyridine group, a pyrimidine group, a pyrazine group, a
pyridazine group, a naphthalene group, an anthracene group,
a tetracene group, a phenanthrene group, a dihydronaphtha-
lene group, a phenalene group, a benzothiophene group, a
60 benzofuran group, an indene group, and an indole group;
and

a pentadiene group, a cyclohexane group, an adamantane group, a bicyclo[2.2.1]heptane group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a 65 pyridazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a


29

benzofuran group, an indene group, and an indole group, each substituted with at least one R_{1a} ,

but embodiments of the present disclosure are not limited thereto.

R_{1a} is the same as described above in connection with R_1 .

In one or more embodiments, the organometallic compound may be represented by Formula 1-1A:



wherein, in Formula 1-1A,

M , T_1 , T_2 , $b1$, $b2$, X_{51} , and X_{52} are the same as described above,

X_{11} may be N or C(R_{11}), X_{12} may be N or C(R_{12}), X_{13} may be N or C(R_{13}), X_{21} may be N or C(R_{21}), X_{22} may be N or C(R_{22}), X_{23} may be N or C(R_{23}), X_{31} may be N or C(R_{31}), X_{32} may be N or C(R_{32}), X_{33} may be N or C(R_{33}), X_{41} may be N or C(R_{41}), X_{42} may be N or C(R_{42}), X_{43} may be N or C(R_{43}), and X_{44} may be N or C(R_{44}),

R_{11} to R_{13} are each independently the same as described above in connection with R_1 , and two of R_{11} to R_{13} may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

R_{21} to R_{23} are each independently the same as described above in connection with R_2 , and two of R_{21} to R_{23} may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

R_{31} to R_{33} are each independently the same as described above in connection with R_3 , and two of R_{31} to R_{33} may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

R_{41} to R_{44} are each independently the same as described above in connection with R_4 , and two of R_{41} to R_{44} may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two of R_{11} to R_{13} , R_{21} to R_{23} , R_{31} to R_{33} , and R_{41} to R_{44} may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

R_{61} and R_{71} are each independently the same as described above in connection with R_1 ,

$a61$ and $a71$ may each independently be 0, 1, 2, or 3,

T_4 may be C, Si, or P,

T_5 may be a single bond, $^*O^*$, $^*S^*$, $^*C(R_7)(R_8)^*$, $^*C(R_7)=^*$, $^*C(R_8)=^*$, $^*C(R_7)=C(R_8)^*$, $^*C(=O)^*$, $^*C(=S)^*$, $^*C\equiv C^*$, $^*N(R_7)^*$, $^*Si(R_7)(R_8)^*$, and $^*P(R_7)(R_8)^*$,


30

R_7 and R_8 are the same as described above in connection with R_5 , and


* and * each indicate a binding site to a neighboring atom.

The organometallic compound may be represented by one of Formulae 1(1) to 1(20):


1(1)



1(2)




1(3)








31

-continued

**32**


-continued



33


-continued

1(10)


**34**

-continued


1(13)




1(11)




1(14)



1(12)




1(15)



35


-continued



1(16)


36

-continued




1(19)

1(17)



1(18)



50

wherein, in Formulae 1(1) to 1(20),

M, T₁ to T₃, and b₁ to b₃ are the same as described above,

55 X₃₉ may be C(R_{39a})(R_{39b}), N(R₃₉), O, S, or Si(R_{39a})(R_{39b}),

R₁₁ to R₁₃ are each independently the same as described above in connection with R₁,




60 R₂₁ to R₂₃ are each independently the same as described above in connection with R₂,

R₃₁ to R₃₇, R₃₉, R_{39a}, and R_{39b} are each independently the same as described above in connection with R₃, and

65 R₄₁ to R₄₄ may be understood by referring to the description provided herein in connection with R₄.

37

In one or more embodiments, the organometallic compound may be one of Compounds 1 to 132:

**38**

-continued

4

1 5

10

15

20

25

2

30

35

40

45

3

50




55

60

65


5

6



39

-continued




7

5

10

15

20




8

30

35

40

45



9

50


55

60


65

40


-continued



10



11




12

41

-continued

13



5

10


15

20

42


-continued

16



14 25

17




30

35


40

45



15

18




50

55





60

65



43

-continued



44

-continued

19

23

5

10

15

20

20

25

24

30

21

35

40

45

25




50

22

55


60

65



45

-continued



26

5

10

15

20

25


30

35

40

46

-continued



28

27


45

50


55

60

65






29






47

-continued


**48**

-continued



49

-continued



36

5


10

15

20

50


-continued



39

37 25

40




30

35


40

45



38

41




50

55


60

65



51

-continued




42

5

10

15

20




43

30

35

40

45



44

50


55

60


65

52


-continued



45




46



47

53

-continued



48


5

10

15

20

49 25




30

35

40

45

50



50


55

60

65


54

-continued




51

52




53



55

-continued

54



5


10

15

20

55

25




30

35

40

45

56



50

55


60

65


56

-continued


57



58




59



57

-continued



60

5

10


15

20

25

58

-continued



63

25



61

30

35

40

45



64



62

50

55

60




65



65




59

-continued




60

-continued



61

-continued



72

5

10

15

20

73


25

30

35

40


74 45



65


62

-continued




75

76



77



50


55

60

63

-continued

78



5


10

15

20

25


79



40

45

80




65

64

-continued

81



25

82


79

30

35

40

45



80


83

50

55


60

65



65

-continued



84

5


10

15

20

66


-continued



87

85 25

88




30

35


40

45



86 50


89



55


60

65



67

-continued




90

5

10

15

20




91

25

30

35

40



92

50


55

60

65


68

-continued




93

94






95






69

-continued



70

-continued



96

5

10

15

20

97 25

30

35

40

45

98

50

55

60

65




99

100

101

71

-continued



72

-continued

102

105

5

10

15

20

103

30

35

40

45




104

50

55

60

65






106

107

73

-continued



74

-continued

108

111

5

10

15

20

109

25

30

35

40

45




110

50

55

60

65






112

113




75

-continued



76

-continued



114

117

5

10

15

20

118

25

115

30

35

40

45

119

116

50





55

60

65

77

-continued

**78**

-continued

120

124

5

10

15

20

121

25

30

35

122

40

45

123

50




55

60

65





125

126



79

-continued

**80**

-continued

127

131

5

10

15

128

20

132

25

30

129

35

40

45



50

130

55

60

65




In Formula 1, X_1 may be N, a bond between X_1 and M may be a covalent bond, X_2 to X_4 may each independently be N or C, at least one of X_2 to X_4 may be C, one bond selected from a bond between X_2 and M, a bond between X_3 and M, and a bond between X_4 and M may be a covalent bond, and the remaining two bonds may each be a coordinate bond. That is, the organometallic compound essentially includes a covalent bond between one N and M and a covalent bond between one C and M in the molecular structure (see Formula 1-1'). Since the covalent bond between N and M increases a spin density of the metal M, a maximum emission wavelength of the organometallic compound represented by Formula 1 may be easily controlled, and an organic light-emitting device including the organometallic compound may have excellent efficiency.

Also, Formula 1 essentially includes a 5-membered ring represented by CY_5 , and a cyclometallated ring formed by CY_5 , CY_1 , CY_2 , and M in Formula 1 is a 6-membered ring, a 7-membered ring, or an 8-membered ring (see Formula 1-1'). Accordingly, since charge mobility of the organometallic compound including a ligand represented by Formula 1-1' is improved and an energy level control is facilitated, an organic light-emitting device including the organometallic compound may have improved efficiency and roll-off.

81

82

6-membered ring,
7-membered ring, or
8-membered ring



Formula 1-1'


For example, a highest occupied molecular orbital (HOMO) energy level, a lowest unoccupied molecular orbital (LUMO) energy level, a singlet (S_1) energy level, and a triplet (T_1) energy level of Compounds 1, 32, 43, 49, 55, 61, A, and B were evaluated by a density functional theory (DFT) method of a Gaussian program (the structure was optimized at B3LYP, 6-31G(d,p) level). Results thereof are shown in Table 1.

TABLE 1


Compound No.	HOMO (eV)	LUMO (eV)	S_1 energy level (eV)	T_1 energy level (eV)
1	-4.406	-1.610	2.270	2.025
32	-4.535	-1.733	2.323	2.029
43	-4.355	-1.871	2.011	1.769
49	-4.440	-1.680	2.248	2.001
55	-4.414	-1.735	2.157	1.954
61	-4.350	-1.863	2.075	1.901
A	-5.850	-4.548	1.302	-0.208
B	-4.418	-1.584	2.230	1.971

TABLE 1-continued


Compound No.	HOMO (eV)	LUMO (eV)	S_1 energy level (eV)	T_1 energy level (eV)
--------------	-----------	-----------	-------------------------	-------------------------



32



1




43


83

TABLE 1-continued


Compound		S ₁ energy level		T ₁ energy level
No.	HOMO (eV)	LUMO (eV)	(eV)	(eV)




49



55



61




Compound A

84

TABLE 1-continued

Compound		S ₁ energy level		T ₁ energy level
No.	HOMO (eV)	LUMO (eV)	(eV)	(eV)



Compound B

From Table 1, it is confirmed that the organometallic compound represented by Formula 1 has electric characteristics suitable for use in an electric device, for example, for use as a dopant for an organic light-emitting device.

Synthesis methods of the organometallic compound represented by Formula 1 may be understood by one of ordinary skill in the art by referring to Synthesis Examples provided below.

The organometallic compound represented by Formula 1 is suitable for use in an organic layer of an organic light-emitting device, for example, for use as a dopant in an emission layer of the organic layer. Thus, another aspect provides an organic light-emitting device that includes:

- a first electrode;
 - a second electrode; and
 - an organic layer disposed between the first electrode and the second electrode,
- wherein the organic layer includes an emission layer and at least one of the organometallic compounds represented by Formula 1.

Due to the inclusion of the organic layer including the organometallic compound represented by Formula 1, the organic light-emitting device may have low driving voltage, high efficiency, high power, high quantum efficiency, a long lifespan, a low roll-off ratio, and excellent color purity.

The organometallic compound represented by Formula 1 may be used between a pair of an organic light-emitting device. For example, the organometallic compound represented by Formula 1 may be included in the emission layer. In this regard, the organometallic compound may act as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound represented by Formula 1 is smaller than an amount of the host).

The expression “(an organic layer) includes at least one of organometallic compounds” as used herein may include an embodiment in which “(an organic layer) includes identical organometallic compounds represented by Formula 1” and an embodiment in which “(an organic layer) includes two or more different organometallic compounds represented by Formula 1.”

For example, the organic layer may include, as the organometallic compound, only Compound 1. In this embodiment, Compound 1 may be included in an emission layer of the organic light-emitting device. In one or more embodiments, the organic layer may include, as the organometallic compound, Compound 1 and Compound 2. In this embodiment, Compound 1 and Compound 2 may be included in an identical layer (for example, Compound 1 and Compound 2 may both be included in an emission layer).

The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode; or the first

electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.

In one or more embodiments, in the organic light-emitting device, the first electrode is an anode; the second electrode is a cathode; the organic layer further includes a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode; the hole transport region includes a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof; and the electron transport region includes a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

The term "organic layer" as used herein refers to a single layer and/or a plurality of layers disposed between the first electrode and the second electrode of the organic light-emitting device. The "organic layer" may include, in addition to an organic compound, an organometallic complex including metal.

FIG. 1 is a schematic view of an organic light-emitting device 10 according to an embodiment. Hereinafter, the structure of an organic light-emitting device according to an embodiment and a method of manufacturing an organic light-emitting device according to an embodiment will be described in connection with FIG. 1. The organic light-emitting device 10 includes a first electrode 11, an organic layer 15, and a second electrode 19, which are sequentially stacked in this stated order.

A substrate may be additionally disposed under the first electrode 11 or above the second electrode 19. For use as the substrate, any substrate used in general organic light-emitting devices may be used, and the substrate may be a glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.

In one or more embodiments, the first electrode 11 may be formed by depositing or sputtering a material for forming the first electrode 11 on the substrate. The first electrode 11 may be an anode. The material for forming the first electrode 11 may be selected from materials with a high work function to facilitate hole injection. The first electrode 11 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode 11 may be an indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO_2), or zinc oxide (ZnO). In one or more embodiments, the material for forming the first electrode 11 may be metal, such as magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag).

The first electrode 11 may have a single-layered structure or a multi-layered structure including two or more layers. For example, the first electrode 11 may have a three-layered structure of ITO/Ag/ITO, but the structure of the first electrode 11 is not limited thereto.

The organic layer 15 is disposed on the first electrode 11.

The organic layer 15 may include a hole transport region, an emission layer, and an electron transport region.

The hole transport region may be disposed between the first electrode 11 and the emission layer.

The hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof.

The hole transport region may include only either a hole injection layer or a hole transport layer. In one or more

embodiments, the hole transport region may have a hole injection layer/hole transport layer structure or a hole injection layer/hole transport layer/electron blocking layer structure, which are sequentially stacked in this stated order from the first electrode 11.


When the hole transport region includes a hole injection layer (HIL), the hole injection layer may be formed on the first electrode 11 by using one or more suitable methods, for example, vacuum deposition, spin coating, casting, and/or Langmuir-Blodgett (LB) deposition.

When a hole injection layer is formed by vacuum deposition, the deposition conditions may vary depending on a material that is used to form the hole injection layer, and the structure and thermal characteristics of the hole injection layer. For example, the deposition conditions may include a deposition temperature of about 100° C. to about 500° C., a vacuum pressure of about 10^{-8} torr to about 10^{-3} torr, and a deposition rate of about 0.01 Angstroms per second ($\text{\AA}/\text{sec}$) to about 100 $\text{\AA}/\text{sec}$. However, the deposition conditions are not limited thereto.

When the hole injection layer is formed using spin coating, coating conditions may vary according to the material used to form the hole injection layer, and the structure and thermal properties of the hole injection layer. For example, a coating speed may be from about 2,000 revolutions per minute (rpm) to about 5,000 rpm, and a temperature at which heat treatment is performed to remove a solvent after coating may be from about 80° C. to about 200° C. However, the coating conditions are not limited thereto.

Conditions for forming a hole transport layer and an electron blocking layer may be understood by referring to conditions for forming the hole injection layer.


The hole transport region may include at least one selected from m-MTDATA, TDATA, 2-TNATA, NPB, β -NPB, TPD, Spiro-TPD, Spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4',4''-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzene sulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrene sulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrene sulfonate) (PANI/PSS), a compound represented by Formula 201 below, and a compound represented by Formula 202 below:




m-MTDATA

87


-continued



TDATA




2-TNATA




NPB

88

-continued




β -NPB




TPD

25




Spiro-TPD

40



Spiro-NPB

55




methylated NPB


65

89

-continued




TAPC




HMTPD

Formula 201



Formula 202



Ar₁₀₁ to Ar₁₀₂ in Formula 201 may each independently be selected from:

a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group; and

90

a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

xa and xb in Formula 201 may each independently be an integer from 0 to 5, or 0, 1, or 2. For example, xa may be 1 and xb may be 0, but xa and xb are not limited thereto.

R₁₀₁ to R₁₀₈, R₁₁₁ to R₁₁₉, and R₁₂₁ to R₁₂₄ in Formulae 201 and 202 may each independently be selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group (for example, a methyl group, an ethyl group, a propyl group, a butyl group, pentyl group, a hexyl group, or the like), and a C₁-C₁₀ alkoxy group (for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, or the like);

a C₁-C₁₀ alkyl group and a C₁-C₁₀ alkoxy group, each substituted with at least one selected from;

a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group; and

a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, and a C₁-C₁₀ alkoxy group, but embodiments of the present disclosure are not limited thereto.


91

R₁₀₉ in Formula 201 may be selected from:

a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group; and


a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group.

In one or more embodiments, the compound represented by Formula 201 may be represented by Formula 201A, but embodiments of the present disclosure are not limited thereto:



R₁₀₁, R₁₁₁, R₁₁₂, and R₁₀₉ in Formula 201A may be the same as described above.


For example, the compound represented by Formula 201 and the compound represented by Formula 202 may be selected from compounds HT1 to HT20 illustrated below, but embodiments of the present disclosure are not limited thereto.




92

-continued

HT2




HT3



93


-continued

HT4

**94**

-continued

HT6




25

30

35

40

HT5



45


50

55

60

65


HT7



95

-continued

HT8



5


10

15

20

HT9

25




30

35

40

HT10

45




50

55

96

-continued

HT11



5

10

15

20

25


30

HT12

35

40

45




50

55

HT13

60


65



97

-continued

HT14



5


10

15

98


-continued

HT18



HT19

HT15




20

25

30

HT16




35

40

45

HT17



50

55

60

65



A thickness of the hole transport region may be in a range of about 100 Angstroms (Å) to about 10,000 Å, for example, about 100 Å to about 1,000 Å. When the hole transport region includes at least one of a hole injection layer and a hole transport layer, a thickness of the hole injection layer may be in a range of about 100 Å to about 10,000 Å, for example, about 100 Å to about 1,000 Å, and a thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, for example about 100 Å to about 1,500 Å. While not wishing to be bound by theory, it is understood that when the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.

The hole transport region may further include, in addition to these materials, a charge-generation material for the improvement of conductive properties. The charge-generation material may be homogeneously or non-homogeneously dispersed in the hole transport region.

The charge-generation material may be, for example, a p-dopant. The p-dopant may be one selected from a quinone

99

derivative, a metal oxide, and a cyano group-containing compound, but embodiments of the present disclosure are not limited thereto. Non-limiting examples of the p-dopant are a quinone derivative, such as tetracyanoquinonodimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonodimethane (F4-TCNQ); a metal oxide, such as a tungsten oxide or a molybdenum oxide; and a cyano group-containing compound, such as Compound HT-D1 below, but embodiments of the present disclosure are not limited thereto.



The hole transport region may include a buffer layer.

Also, the buffer layer may compensate for an optical resonance distance according to a wavelength of light emitted from the emission layer, and thus, efficiency of a formed organic light-emitting device may be improved.


Then, an emission layer (EML) may be formed on the hole transport region by vacuum deposition, spin coating, casting, LB deposition, or the like. When the emission layer is formed by vacuum deposition or spin coating, the deposition or coating conditions may be similar to those applied to form the hole injection layer although the deposition or coating conditions may vary according to the material that is used to form the emission layer.

Meanwhile, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be selected from materials for the hole transport region described above and materials for a host to be explained later. However, the material for the electron blocking layer is not limited thereto. For example, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be mCP, which will be explained later.


The emission layer may include a host and a dopant, and the dopant may include the organometallic compound represented by Formula 1.

100


The host may include at least one selected from TPBi, TBADN, ADN (also referred to as "DNA"), CBP, CDBP, TCP, mCP, Compound H50, and Compound H51:




TPBi




TBADN



ADN




CBP




CDBP

101


-continued




TCP



mCP




Compound H50



Compound H51

In one or more embodiments, the host may further include a compound represented by Formula 301 below.



Formula 301

102

Ar_{111} to Ar_{112} in Formula 301 may each independently be selected from:

a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group; and

- 5 a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.

Ar_{113} to Ar_{116} in Formula 301 may each independently be selected from:

- 10 a C_1 - C_{10} alkyl group, a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group; and

- a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.


g, h, i, and j in Formula 301 may each independently be an integer from 0 to 4, and may be, for example, 0, 1, or 2.

Ar_{113} to Ar_{116} in Formula 301 may each independently be selected from:

- 20 a C_1 - C_{10} alkyl group, substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group;

a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl, a phenanthrenyl group, and a fluorenyl group;


- 25 a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group, each substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group; and



but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, the host may include a compound represented by Formula 302 below:

Formula 302




Ar_{122} to Ar_{125} in Formula 302 are the same as described in detail in connection with Ar_{113} in Formula 301.

- 65 Ar_{126} and Ar_{127} in Formula 302 may each independently be a C_1 - C_{10} alkyl group (for example, a methyl group, an ethyl group, or a propyl group).


103

k and l in Formula 302 may each independently be an integer from 0 to 4. For example, k and l may be 0, 1, or 2.


The compound represented by Formula 301 and the compound represented by Formula 302 may include Compounds H1 to H42 illustrated below, but embodiments of the present disclosure are not limited thereto:




H1




H2




H3



H4




H5




H6

104


-continued




H7




H8




H9



H10




H11



H12


105

-continued



106


-continued



107


-continued

H23




5

10




H24 15

20




H25

30



H26

40




H27

65


108

-continued


H28




H29




H30




H31



H32




H33



109

-continued

H34




5

10

15

20

H35




30

35

40

H36



45

50

55


60

65


110

-continued


H37



H38




H39



111

-continued



When the organic light-emitting device is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and a blue emission layer. In one or more embodiments, due to a stack structure including a red emission layer, a green emission layer, and/or a blue emission layer, the emission layer may emit white light.

112

When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 parts to about 15 parts by weight based on 100 parts by weight of the host, but is not limited thereto.

A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. While not wishing to be bound by theory, it is understood that when the thickness of the emission layer is within this range, excellent light emission characteristics may be obtained without a substantial increase in driving voltage.


Then, an electron transport region may be disposed on the emission layer.

The electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.


For example, the electron transport region may have a hole blocking layer/electron transport layer/electron injection layer structure or an electron transport layer/electron injection layer structure, but the structure of the electron transport region is not limited thereto. The electron transport layer may have a single-layered structure or a multi-layered structure including two or more different materials.

Conditions for forming the hole blocking layer, the electron transport layer, and the electron injection layer which constitute the electron transport region may be understood by referring to the conditions for forming the hole injection layer.

When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one selected from BCP, Bphen, and BAQ but is not limited thereto.



BCP





Bphen


A thickness of the hole blocking layer may be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. While not wishing to be bound by theory, it is understood that when the thickness of the hole blocking layer is within these ranges, the hole blocking layer may have excellent hole blocking characteristics without a substantial increase in driving voltage.

113


The electron transport layer may further include at least one selected from BCP, Bphen, Alq₃, BALq, TAZ, and NTAZ:

Alq₃

BALq



TAZ




NTAZ

114

In one or more embodiments, the electron transport layer may include at least one of ET1 and ET2, but embodiments of the present disclosure are not limited thereto:

5


ET1



25

30

ET2




50

A thickness of the electron transport layer may be in a range of about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron transport layer is within the range described above, the electron transport layer may have satisfactory electron transport characteristics without a substantial increase in driving voltage.

Also, the electron transport layer may further include, in addition to the materials described above, a metal-containing material.

The metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (lithium quinolate, LiQ) or ET-D2.



The electron transport region may include an electron injection layer (EIL) that promotes flow of electrons from the second electrode **19** thereinto.

The electron injection layer may include at least one selected from LiF, NaCl, CsF, Li₂O, and BaO.

A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, and, for example, about 3 Å to about 90 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron injection layer is within the range described above, the electron injection layer may have satisfactory electron injection characteristics without a substantial increase in driving voltage.

The second electrode **19** is disposed on the organic layer **15**. The second electrode **19** may be a cathode. A material for forming the second electrode **19** may be metal, an alloy, an electrically conductive compound, and a combination thereof, which have a relatively low work function. For example, lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be formed as the material for forming the second electrode **19**. To manufacture a top-emission type light-emitting device, a transmissive electrode formed using ITO or IZO may be used as the second electrode **19**.

Hereinbefore, the organic light-emitting device has been described with reference to FIG. 1, but is not limited thereto.

Another aspect provides a diagnosis composition including at least one organometallic compound represented by Formula 1.

The organometallic compound represented by Formula 1 provides high luminescent efficiency. Accordingly, a diagnosis composition including the organometallic compound may have high diagnosis efficiency.

The diagnosis composition may be used in various applications including a diagnosis kit, a diagnosis reagent, a biosensor, and a biomarker.

The term “C₁-C₆₀ alkyl group” as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and non-limiting examples thereof include a methyl group, an ethyl group, a propyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group. The term “C₁-C₆₀ alkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₆₀ alkyl group.

ET-D1 The term “C₁-C₆₀ alkoxy group” as used herein refers to a monovalent group represented by —OA₁₀₁ (wherein A₁₀₁ is the C₁-C₆₀ alkyl group), and examples thereof include a methoxy group, an ethoxy group, and an iso-propyloxy group.

ET-D2 The term “C₂-C₆₀ alkenyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon double bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C₂-C₆₀ alkenylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkenyl group.

15 The term “C₂-C₆₀ alkynyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon triple bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethynyl group and a propynyl group. The term “C₂-C₆₀ alkynylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkynyl group.

20 The term “C₃-C₁₀ cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C₃-C₁₀ cycloalkylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkyl group.

30 The term “C₁-C₁₀ heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom and 1 to 10 carbon atoms, and non-limiting examples thereof include a tetrahydrofuranyl group and a tetrahydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkyl group.

40 The term “C₃-C₁₀ cycloalkenyl group” as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms, at least one carbon-carbon double bond in the ring thereof, and no aromaticity. Non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C₃-C₁₀ cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkenyl group.

50 The term “C₁-C₁₀ heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in its ring. Examples of the C₁-C₁₀ heterocycloalkenyl group are a 2,3-dihydrofuranyl group and a 2,3-dihydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkenyl group.

55 The term “C₆-C₆₀ aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and a C₆-C₆₀ arylene group used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Non-limiting examples of the C₆-C₆₀ aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C₆-C₆₀ aryl group and the C₆-C₆₀ arylene group each include two or more rings, the rings may be fused to each other.

The term “C₁-C₆₀ heteroaryl group” as used herein refers to a monovalent group having a cyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, and 1 to 60 carbon atoms. The term “C₁-C₆₀ heteroarylene group” as used herein refers to a divalent group having a carbocyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, and 1 to 60 carbon atoms. Non-limiting examples of the C₁-C₆₀ heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C₁-C₆₀ heteroaryl group and the C₁-C₆₀ heteroarylene group each include two or more rings, the rings may be fused to each other.

The term “C₆-C₆₀ aryloxy group” as used herein indicates —OA₁₀₂ (wherein A₁₀₂ is the C₆-C₆₀ aryl group), and a C₆-C₆₀ arylthio group as used herein indicates —SA₁₀₃ (wherein A₁₀₃ is the C₆-C₆₀ aryl group).

The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group (for example, having 8 to 60 carbon atoms) having two or more rings condensed to each other, only carbon atoms as ring-forming atoms, and no aromaticity in its entire molecular structure. Examples of the monovalent non-aromatic condensed polycyclic group include a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group,” as used herein, refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.

The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group (for example, having 2 to 60 carbon atoms) having two or more rings condensed to each other, a heteroatom selected from N, O, P, Si, and S, other than carbon atoms, as a ring-forming atom, and no aromaticity in its entire molecular structure. Non-limiting examples of the monovalent non-aromatic condensed heteropolycyclic group include a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group,” as used herein, refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.

The term “C₅-C₃₀ carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as ring-forming atoms, 5 to 30 carbon atoms only. The C₅-C₃₀ carbocyclic group may be a monocyclic group or a polycyclic group.

The term “C₁-C₃₀ heterocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, at least one heteroatom selected from N, O, Si, P, and S other than 1 to 30 carbon atoms. The C₁-C₃₀ heterocyclic group may be a monocyclic group or a polycyclic group.

At least one substituent of the substituted C₅-C₃₀ carbocyclic group, the substituted C₂-C₃₀ heterocyclic group, the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₁-C₆₀ heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group;

a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(=O)(Q₁₈)(Q₁₉);

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇) and —P(=O)(Q₂₈)(Q₂₉); —N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇) and —P(=O)(Q₃₈)(Q₃₉); and

Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ may each independently be selected from a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀

119

alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group.

When a group containing a specified number of carbon atoms is substituted with any of the groups listed in the preceding paragraph, the number of carbon atoms in the resulting "substituted" group is defined as the sum of the carbon atoms contained in the original (unsubstituted) group and the carbon atoms (if any) contained in the substituent. For example, when the term "substituted C₁-C₃₀ alkyl" refers to a C₁-C₃₀ alkyl group substituted with C₆-C₃₀ aryl group, the total number of carbon atoms in the resulting aryl substituted alkyl group is C₇-C₆₀.

120


Hereinafter, a compound and an organic light-emitting device according to embodiments are described in detail with reference to Synthesis Examples and Examples. However, the organic light-emitting device is not limited thereto. The wording "B was used instead of A" used in describing Synthesis Examples means that the number of molar equivalents of A used was identical to the number of molar equivalents of B.

EXAMPLES

Synthesis Example 1: Synthesis of Compound 1

Compound 1 was synthesized according to the Reaction Scheme 1.


Reaction Scheme 1



121

122

-continued



1) Synthesis of Intermediate 1-3

4.0 grams (g) (10.66 millimoles, mmol) of Compound 1A, 3.3 g (12.80 mmol) of bis(pinacolato)diboron, 3.1 g (31.98 mmol) of potassium acetate, and 0.78 g (1.07 mmol) of $\text{Pd(dppf)}_2\text{Cl}_2$ were mixed with 150 milliliters (ml) of toluene, and the mixture was heated to a temperature of 120° C. and stirred for 8 hours under reflux. The reactant obtained therefrom was cooled to room temperature. The organic layer was extracted by using 300 ml of water and 300 ml of ethyl acetate. The organic layer was dried by using MgSO_4 and a solvent was evaporated. The residue obtained therefrom was separated and purified by silica gel column chromatography, thereby completing the preparation of 2.1 g (58%) of Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=341.14$ (M+H)⁺

2) Synthesis of Intermediate 1-2

2.1 g (6.17 mmol) of Intermediate 1-3, 1.73 g (5.144 mmol) of Compound 1B, 1.36 g (12.86 mmol) of sodium carbonate, and 0.4 g (0.36 mmol) of $\text{Pd(PPh}_3)_4$ were mixed with 90 ml of tetrahydrofuran (THF), 30 ml of distilled water, and 30 ml of ethanol, and the mixture was heated to a temperature of 100° C. and stirred for 16 hours under reflux. The reactant obtained therefrom was cooled to room temperature. The organic layer was extracted by using 200 ml of water and 200 ml of ethyl acetate. The organic layer was dried by using MgSO_4 , and a solvent was evaporated. The residue obtained therefrom was separated and purified by silica gel column chromatography, thereby completing the preparation of 2.47 g (81%) of Intermediate 1-2. The obtained compound was identified by LC-MS.

LC-MS $m/z=596.28$ (M+H)⁺

3) Synthesis of Intermediate 1-1

2.47 g (4.14 mmol) of Intermediate 1-2, 1.14 g (5.39 mmol) of Compound 1C, 1.72 g (12.43 mmol) of sodium carbonate, and 0.34 g (0.29 mmol) of $\text{Pd(PPh}_3)_4$ were mixed with 90 ml of THF, 30 ml of distilled water, and 30 ml of ethanol, and the mixture was heated to a temperature of 100° C. and stirred for 16 hours under reflux. The reactant obtained therefrom was cooled to room temperature. The organic layer was extracted by using 200 ml of water and 200 ml of ethyl acetate. The organic layer was dried by using MgSO_4 , and a solvent was evaporated. The residue obtained

therefrom was separated and purified by silica gel column chromatography, thereby completing the preparation of 2.6 g (86%) of Intermediate 1-1. The obtained compound was identified by LC-MS.


LC-MS $m/z=727.37$ (M+H)⁺

4) Synthesis of Compound 1

2.6 g (3.58 mmol) of Intermediate 1-1, 1.48 g (3.58 mmol) of potassium tetrachloroplatinate, and 100 ml of acetic acid were mixed, and the mixture was heated to a temperature of 130° C. and stirred for 16 hours under reflux. The reactant obtained therefrom was cooled to room temperature, and the organic layer was washed with a sodium bicarbonate aqueous solution, water, and extracted with 200 ml of ethyl acetate. The organic layer was dried by using MgSO_4 and a solvent was evaporated. The residue obtained therefrom was separated and purified by silica gel column chromatography, thereby completing the preparation of 1.48 g (45%) of Compound 1. The obtained compound was identified by LC-MS.

LC-MS $m/z=920.32$ (M+H)⁺

Synthesis Example 2: Synthesis of Compound 2




123

Compound 2 was synthesized in the same manner as in Synthesis Example 1, except that N-(3-bromo-5-methylphenyl)-N-(naphthalen-1-yl)pyridin-2-amine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=934.34$ ($M+H$)⁺


Synthesis Example 3: Synthesis of Compound 3



Compound 3 was synthesized in the same manner as in Synthesis Example 1, except that N-(3-bromo-5-ethylphenyl)-N-(naphthalen-1-yl)pyridin-2-amine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=948.35$ ($M+H$)⁺

Synthesis Example 4: Synthesis of Compound 7




Compound 7 was synthesized in the same manner as in Synthesis Example 1, except that N-(3-bromophenyl)-N-phenylpyridin-2-amine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=870.31$ ($M+H$)⁺

124


Synthesis Example 5: Synthesis of Compound 8



Compound 8 was synthesized in the same manner as in Synthesis Example 1, except that N-(3-bromo-5-methylphenyl)-N-phenylpyridin-2-amine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=884.32$ ($M+H$)⁺

Synthesis Example 6: Synthesis of Compound 9




Compound 9 was synthesized in the same manner as in Synthesis Example 1, except that N-(3-bromo-5-ethylphenyl)-N-phenylpyridin-2-amine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=898.34$ ($M+H$)⁺

125


Synthesis Example 7: Synthesis of Compound 19



Compound 19 was synthesized in the same manner as in Synthesis Example 1, except that 2,6-dichloropyridine was used instead of Compound 1B in synthesizing Intermediate 1-2. The obtained compound was identified by LC-MS.

LC-MS $m/z=732.16$ ($M+H$)⁺


Synthesis Example 8: Synthesis of Compound 20



Compound 20 was synthesized in the same manner as in Synthesis Example 1, except that 2,6-dichloro-4-methylpyridine was used instead of Compound 1B in synthesizing Intermediate 1-2. The obtained compound was identified by LC-MS.

LC-MS $m/z=746.18$ ($M+H$)⁺


Synthesis Example 9: Synthesis of Compound 21

**126**

Compound 21 was synthesized in the same manner as in Synthesis Example 1, except that 4-(tert-butyl)-2,6-dichloropyridine was used instead of Compound 1B in synthesizing Intermediate 1-2. The obtained compound was identified by LC-MS.

LC-MS $m/z=788.23$ ($M+H$)⁺


Synthesis Example 10: Synthesis of Compound 25



Compound 25 was synthesized in the same manner as in Synthesis Example 1, except that a (3,6-dimethyl-9H-carbazol-1-yl)boronic acid was used instead of Compound 1C in synthesizing Intermediate 1-1. The obtained compound was identified by LC-MS.

LC-MS $m/z=948.35$ ($M+H$)⁺

Synthesis Example 11: Synthesis of Compound 28




127

Compound 28 was synthesized in the same manner as in Synthesis Example 1, except that a (3,6-di-tert-butyl-9H-carbazol-1-yl)boronic acid was used instead of Compound 1C in synthesizing Intermediate 1-1. The obtained compound was identified by LC-MS.

LC-MS $m/z=1032.45$ (M+H)⁺


Synthesis Example 12: Synthesis of Compound 31



Compound 31 was synthesized in the same manner as in Synthesis Example 1, except that 2-(3-bromophenyl)-5-(tert-butyl)pyridine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=835.33$ (M+H)⁺

Synthesis Example 13: Synthesis of Compound 32




Compound 32 was synthesized in the same manner as in Synthesis Example 1, except that 2-(3-bromophenoxy)pyridine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=779.26$ (M+H)⁺

128


Synthesis Example 14: Synthesis of Compound 41



Compound 41 was synthesized in the same manner as in Synthesis Example 1, except that, in forming Compound 1, 2-(5-bromo-[1,1'-biphenyl]-3-yl)-4-phenylpyridine was used instead of Compound 1A, and a (3,6-di-tert-butyl-9H-carbazol-1-yl)boronic acid was used instead of Compound 1C. The obtained compound was identified by LC-MS.

LC-MS $m/z=931.33$ (M+H)⁺

Synthesis Example 15: Synthesis of Compound 103




Compound 103 was synthesized in the same manner as in Synthesis Example 1, except that 2-(3-bromophenoxy)pyridine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=795.26$ (M+H)⁺

129

Synthesis Example 16: Synthesis of Compound 115



Compound 115 was synthesized in the same manner as in
Synthesis Example 1, except that 2-((3-bromophenyl)dimethylsilyl)pyridine was used instead of Compound 1A in synthesizing Intermediate 1-3. The obtained compound was identified by LC-MS.

LC-MS $m/z=837.29$ ($M+H$)⁺

Example 1

An ITO glass substrate was cut to a size of 50 mm×50
mm×0.5 mm (mm=millimeters), sonicated in acetone, isopropyl alcohol, and pure water each for 15 minutes, and then, washed by exposing the ITO glass substrate to UV irradiation and ozone for 30 minutes.

Then, m-MTDATA was deposited on an ITO electrode (anode) of the ITO glass substrate at a deposition rate of 1 Angstroms per second ($\text{\AA}/\text{sec}$) to form a hole injection layer having a thickness of 600 Angstroms ($\text{\AA}$), and then, α -NPD was deposited on the hole injection layer at a deposition rate of 1 $\text{\AA}/\text{sec}$ to form a hole transport layer having a thickness of 250 $\text{\AA}$.

130

Compound 1 (dopant) and CBP (host) were each co-deposited on the hole transport layer at a deposition rate of 0.1 $\text{\AA}/\text{sec}$ and 1 $\text{\AA}/\text{sec}$ to form an emission layer having a thickness of 400 $\text{\AA}$.

BAIq was deposited on the emission layer at a deposition rate of 1 $\text{\AA}/\text{sec}$ to form a hole blocking layer having a thickness of 50 $\text{\AA}$, Alq_3 was deposited on the hole blocking layer to form an electron transport layer having a thickness of 300 $\text{\AA}$, LiF was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 $\text{\AA}$, and Al was vacuum-deposited on the electron injection layer to form a second electrode (cathode) having a thickness of 1,200 $\text{\AA}$, thereby completing the manufacture of an organic light-emitting device having a structure of ITO/m-MTDATA (600 $\text{\AA}$)/ α -NPD (250 $\text{\AA}$)/CBP+10% (Compound 1) (400 $\text{\AA}$)/BAIq (50 $\text{\AA}$)/ Alq_3 (300 $\text{\AA}$)/LiF (10 $\text{\AA}$)/Al (1,200 $\text{\AA}$).

Examples 2 to 4 and Comparative Example 1

Organic light-emitting devices of Examples 2 to 4 and Comparative Example 1 were manufactured in the same manner as in Example 1, except that Compounds shown in Table 2 were each used instead of Compound 1 as a dopant in forming an emission layer.

Evaluation Example: Evaluation of Characteristics of Organic Light-Emitting Devices

The driving voltage, efficiency, power, color purity, quantum efficiency, and roll-off ratio of the organic light-emitting devices manufactured according to Examples 1 to 4 and Comparative Example 1 were evaluated. Results thereof are shown in Table 2. This evaluation was performed by using a current-voltage meter (Keithley 2400) and a luminance meter (Minolta Cs-1000A). The roll-off ratio was calculated by Equation 20:


$$\text{Roll-off ratio} = \{1 - (\text{efficiency (at 9000 nit)} / \text{maximum emission efficiency})\} \times 100\% \quad \text{Equation 20}$$

TABLE 2


	Dopant	Driving voltage (V)	Efficiency (cd/A)	Power (lm/W)	CIEx	CIEx	Quantum Efficiency (%)	Roll-off ratio (%)
Example 1	Compound 1	3.809	41.426	34.168	0.576	0.42	20.64	7.8
Example 2	Compound 7	3.712	40.413	33.519	0.572	0.415	20.53	8.1
Example 3	Compound 31	3.365	65.547	61.214	0.512	0.481	22.78	4.8
Example 4	Compound 32	3.420	62.183	58.831	0.525	0.471	22.82	6.2
Comparative Example 1	Compound B	5.371	16.461	9.63	0.642	0.354	13.32	25.5

TABLE 2-continued


Dopant	Driving voltage (V)	Efficiency (cd/A)	Power (lm/W)	ClEx	ClEy	Quantum Efficiency (%)	Roll-off ratio (%)
--------	---------------------------	----------------------	-----------------	------	------	------------------------------	--------------------------



1





7



31

TABLE 2-continued

Dopant	Driving voltage (V)	Efficiency (cd/A)	Power (lm/W)	CIE _x	CIE _y	Quantum Efficiency (%)	Roll-off ratio (%)
							
32							



Referring to Table 2, it was determined that the organic light-emitting devices of Examples 1 to 4 had excellent driving voltage, efficiency, power, color purity, quantum efficiency, and roll-off ratio characteristics, compared to those of the organic light-emitting device of Comparative Example 1.


Since the organometallic compound has excellent electrical characteristics and thermal stability, an organic light-emitting device including the organometallic compound has excellent driving voltage, efficiency, power, color purity, quantum efficiency, and roll-off ratio characteristics. Also, since the organometallic compound has excellent phosphorescence characteristics, a diagnosis composition having high diagnosis efficiency may be provided by using the organometallic compound.

It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.

While one or more embodiments have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure as defined by the following claims.

What is claimed is:

1. An organometallic compound represented by Formula 1:



135

and M, a bond between X_3 and M, and a bond between X_4 and M is a covalent bond; and each of the remaining two bonds is a coordinate bond,

Y_1 to Y_9 are each independently C or N,

a bond between Y_1 and Y_2 , a bond between Y_1 and Y_3 , a bond between X_2 and Y_4 , a bond between X_2 and Y_5 , a bond between X_3 and Y_6 , a bond between X_3 and Y_7 , a bond between X_4 and Y_8 , a bond between X_4 and Y_9 , a bond between Y_2 and X_{52} , and a bond between X_{51} and X_{52} are each independently a single bond or a double bond,

CY_1 to CY_5 are each independently selected from a C_5 - C_{30} carbocyclic group and a C_1 - C_{30} heterocyclic group,

a cyclometallated ring formed by CY_5 , CY_1 , CY_2 , and M is a 6-membered ring, a 7-membered ring, or an 8-membered ring,

T_1 to T_3 are each independently selected from $*-O-*$, $*-S-*$, $*-C(R_5)(R_6)-*$, $*-C(R_5)=*$, $*-C(R_5)-*$, $*-C(R_5)=C(R_6)-*$, $*-C(=O)-*$, $*-C(=S)-*$, $*-C\equiv C-*$, $*-N(R_5)-*$, $*-Si(R_5)(R_6)-*$, and $*-P(R_5)(R_6)-*$,

R_5 and R_6 are optionally linked via a first linking group to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

b_1 to b_3 are each independently 0, 1, 2, or 3, wherein when b_1 is zero, $*(T_1)_{b_1}-*$ is a single bond, when b_2 is zero, $*(T_2)_{b_2}-*$ is a single bond, and when b_3 is zero, $*(T_3)_{b_3}-*$ is a single bond,

X_{51} is selected from O, S, N, $N(R_{51})$, $C(R_{51})$, (R_{52}) , $Si(R_{51})(R_{52})$, and $C(=O)$,

X_{52} is selected from O, S, N, $N(R_{53})$, $C(R_{53})$, (R_{54}) , $Si(R_{53})(R_{54})$, and $C(=O)$,

R_{51} and R_{52} are optionally linked via a second linking group to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

R_{53} and R_{54} are optionally linked via a third linking group to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

R_{51} and R_{53} are optionally linked via a fourth linking group to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

R_1 to R_6 and R_{51} to R_{54} are each independently selected from hydrogen, deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-SF_5$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-N(Q_1)(Q_2)$, $-Si(Q_3)(Q_4)(Q_6)$, $-B(Q_6)(Q_7)$, and $-P(=O)(Q_8)(Q_9)$,

136

tuted monovalent non-aromatic condensed heteropolycyclic group, $-N(Q_1)(Q_2)$, $-Si(Q_3)(Q_4)(Q_6)$, $-B(Q_6)(Q_7)$, and $-P(=O)(Q_8)(Q_9)$,

a_1 to a_4 are each independently 0, 1, 2, 3, 4, or 5,

two of groups R_1 in the number of a_1 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two of groups R_2 in the number of a_2 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two of R_3 in the number of a_3 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two of groups R_4 in the number of a_4 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two or more neighboring groups selected from R_1 to R_4 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

$*$ and $*$ each indicate a binding site to a neighboring atom, and

at least one substituent of the substituted C_5 - C_{30} carbocyclic group, the substituted C_1 - C_{30} heterocyclic group, the substituted C_1 - C_{60} alkyl group, the substituted C_2 - C_{60} alkenyl group, the substituted C_2 - C_{60} alkynyl group, the substituted C_1 - C_{60} alkoxy group, the substituted C_3 - C_{10} cycloalkyl group, the substituted C_1 - C_{10} heterocycloalkyl group, the substituted C_3 - C_{10} cycloalkenyl group, the substituted C_1 - C_{10} heterocycloalkenyl group, the substituted C_6 - C_{60} aryl group, the substituted C_6 - C_{60} aryloxy group, the substituted C_6 - C_{60} arylthio group, the substituted C_1 - C_{60} heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group is selected from:

deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-CD_3$, $-CD_2H$, $-CDH_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, and a C_1 - C_{60} alkoxy group;

a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, and a C_1 - C_{60} alkoxy group, each substituted with at least one selected from deuterium, $-F$, $-Cl$, $-Br$, $-I$, $-CD_3$, $-CD_2H$, $-CDH_2$, $-CF_3$, $-CF_2H$, $-CFH_2$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, $-N(Q_{11})(Q_{12})$, $-Si(Q_{13})(Q_{14})(Q_{15})$, $-B(Q_{16})(Q_{17})$, and $-P(=O)(Q_{18})(Q_{19})$;

137

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(=O)(Q₂₈)(Q₂₉); and

—N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(=O)(Q₃₈)(Q₃₉),


wherein Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one of a C₁-C₆₀ alkyl group and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

2. The organometallic compound of claim 1, wherein CY₁ to CY₄ are each independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinoxaline group, a phenanthroline group, a


138

pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline.

3. The organometallic compound of claim 1, wherein a moiety represented by



in Formula 1 is a group represented by Formula CY1-1:



CY1-1

wherein, in Formula CY1-1,


X₅₁ and X₅₂ are the same as described in claim 1,

X₁₁ is N or C(R₁₁), X₁₂ is N or C(R₁₂), and X₁₃ is N or C(R₁₃),


R₁₁ to R₁₃ are each independently the same as described in connection with R₁ in claim 1, and

* and *' each indicate a binding site to a neighboring atom.

4. The organometallic compound of claim 1, wherein a moiety represented by








in Formula 1 is selected from groups represented by Formulae CY2-1 to CY2-6:



CY2-1

139

-continued




wherein, in Formulae CY2-1 to CY2-4,

X₂₁ is N or C(R₂₁), X₂₂ is N or C(R₂₂), X₂₃ is N or C(R₂₃),
X₂₄ is N or C(R₂₄), X₂₅ is N or C(R₂₅), X₂₆ is N or
C(R₂₆), and X₂₇ is N or C(R₂₇),

R₂₁ to R₂₇ are each independently the same as described in connection with R₂ in claim 1, and

*, *', and *'' each indicate a binding site to a neighboring atom.

5. The organometallic compound of claim 1, wherein a moiety represented by




140

in Formula 1 is selected from groups represented by Formulae CY3-1 to CY3-22:

CY2-2

5


CY3-1



CY2-3

10


CY3-2



CY2-4

20

CY3-3




25

CY2-5

30


CY3-4



CY2-6


35

CY3-5




45

CY3-6



55








CY3-7



65

141

-continued




142

-continued

CY3-8


5



10

CY3-9


15



20

CY3-10


25



30

CY3-11


35



40


CY3-12

45



CY3-13


50



55

CY3-14

60



65

CY3-15

CY3-16

CY3-17


CY3-18

CY3-19

CY3-20


CY3-21

-continued






*, *, and *' each indicate a binding site to a neighboring atom.

6. The organometallic compound of claim 1, wherein a moiety represented by




in Formula 1 is selected from groups represented by Formulae CY4-1 to CY4-8:




-continued


CY4-4




CY4-5




CY4-6



CY4-7



CY4-8



wherein, in Formulae CY4-1 to CY4-8,

X_{41} is N or $C(R_{41})$, X_{42} is N or $C(R_{42})$, X_{43} is N or $C(R_{43})$,
 X_{44} is N or $C(R_{44})$, X_{45} is N or $C(R_{45})$, X_{46} is N or
 $C(R_{46})$, X_{47} is N or $C(R_{47})$, and X_{48} is N or $C(R_{48})$.

R₄₁ to R₄₈ are each independently the same as described in connection with R₄ in claim 1, and

* and *' each indicate a binding site to a neighboring atom.

7. The organometallic compound of claim 1, wherein T₁ to T₃ are each independently selected from *—O—*, *—S—*, *—C(R₅)(R₆)—*, *—N(R₅)—*, *—Si(R₅)(R₆)—*, and *—P(R₅)(R₆)—*.

8. The organometallic compound of claim 1, wherein T_1 to T_3 are each independently selected from $^*-\text{C}(\text{R}_5)(\text{R}_6)-^*$, $^*-\text{Si}(\text{R}_5)(\text{R}_6)-^*$, and $^*-\text{P}(\text{R}_5)(\text{R}_6)-^*$,

R₅ and R₆ are linked via a first linking group, and the first linking group is selected from a single bond, *—O—*, *—S—*, *—C(R₉)(R₁₀)—*, *—C(R₉)=*, *—C(R₉)=*, *—C(R₉)—C(R₁₀)—*, *—C(=O)—*, *—C(=S)—*, *—C≡C—*, *—N(R₉)—*, *—Si(R₉)(R₁₀)—*, and *—P(R₉)(R₁₀)—*, wherein R₉ and R₁₀ are the same as described in connection with R₅ in claim 1, and * and *' each indicate a binding site to a neighboring atom.

9. The organometallic compound of claim 1, wherein b1 is 1 and b2 and b3 are each zero; b2 is 1 and b1 and b3 are each zero; or b3 is 1 and b1 and b2 are each zero.

10. The organometallic compound of claim 1, wherein R_1 to R_6 and R_{51} to R_{54} are each independently selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF₅, a C₁-C₂₀ alkyl group, and a C₁-C₂₀ alkoxy group;

a C₁-C₂₀ alkyl group and a C₁-C₂₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolynyl group, an isoquinolynyl group, a benzoquinolynyl group, a quinoxalynyl group, a quinazolynyl group, a cinnolynyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl

group, an indazolyl group, a purinyl group, a quinolynyl group, an isoquinolynyl group, a benzoquinolynyl group, a quinoxalynyl group, a quinazolynyl group, a cinnolynyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolynyl group, an isoquinolynyl group, a benzoquinolynyl group, a quinoxalynyl group, a quinazolynyl group, a cinnolynyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group; and

—N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉),

wherein Q₁ to Q₉ are each independently selected from:

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCD₂H, —CHDCDH₂, —CHDCH₂, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.

147

11. The organometallic compound of claim 1, wherein R_1 to R_6 and R_{51} to R_{54} are each independently selected from:

hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a quinolinyl group, an isoquinolinyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group;

a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a quinolinyl group, an isoquinolinyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, each substituted with at least one selected from deuterium, —F, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a cyano group, a nitro group, a C₁-C₁₀ alkyl group, a C₁-C₁₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a quinolinyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group; and —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉),

wherein Q₁ to Q₉ are each independently selected from: —CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCD₃, —CHDCD₂H, —CHDCDH₂, —CHDCD₂CD₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl


148

group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.














12. The organometallic compound of claim 1, wherein

R_1 to R_6 and R_{51} to R_{54} are each independently selected from hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅, —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-48, and —Si(Q₃)(Q₄)(Q₅):




149

-continued

**150**


-continued

9-15




5

9-16




10

9-17



15


9-18



20


9-19

25




10-1

30




10-2

35




10-3

40




10-4

45




10-5

50



10-6

55



10-7

60

10-8

65

10-9

10-10

10-11

10-12

10-13

10-14

10-15

10-16











10-17

10-18

10-19

151


-continued

**152**

-continued

10-20


5



10-30

10-21


10



10-31

10-22


15



10-32

10-23


20



10-33

10-24


25



10-34

10-25


30



10-35

10-26


35



10-36

10-27


40



10-37


10-28

45



10-29

50











55

60

65

153

-continued




154

-continued

10-38


5



10


10-39

15



10-40

20



10-41

25

wherein * in Formulae 9-1 to 9-19 and 10-1 to 10-48 indicates a binding site to a neighboring atom.

13. The organometallic compound of claim 1, wherein the organometallic compound is represented by Formula 1-1:


30

10-42

35

10-43

40



45

wherein, in Formula 1-1,

M, T₁ to T₃, b₁ to b₃, X₅₁, and X₅₂ are the same as described in claim 1,

10-44

50

X₁₁ is N or C(R₁₁), X₁₂ is N or C(R₁₂), X₁₃ is N or C(R₁₃), X₂₁ is N or C(R₂₁), X₂₂ is N or C(R₂₂), X₂₃ is N or C(R₂₃), X₃₁ is N or C(R₃₁), X₃₂ is N or C(R₃₂), X₃₃ is N or C(R₃₃), X₄₁ is N or C(R₄₁), X₄₂ is N or C(R₄₂), X₄₃ is N or C(R₄₃), and X₄₄ is N or C(R₄₄),

R₁₁ to R₁₃ are each independently the same as described in connection with R₁ in claim 2, and two of R₁₁ to R₁₃ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

10-45

55

R₂₁ to R₂₃ are each independently the same as described in connection with R₂ in claim 1, and two of R₂₁ to R₂₃ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

60

R₃₁ to R₃₃ are each independently the same as described in connection with R₃ in claim 1, and two of R₃₁ to R₃₃ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,


65

Formula 1-1

155

R₄₁ to R₄₄ are each independently the same as described in connection with R₄ in claim 1, and two of R₄₁ to R₄₄ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group, and two of R₁₁ to R₁₃, R₂₁ to R₂₃, R₃₁ to R₃₃, and R₄₁ to R₄₄ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group.

14. The organometallic compound of claim 1, wherein the organometallic compound is represented by Formula 1-1A:



wherein, in Formula 1-1A,

M, T₁, T₂, b₁, b₂, X₅₁, and X₅₂ are the same as described in claim 1,

X₁₁ is N or C(R₁₁), X₁₂ is N or C(R₁₂), X₁₃ is N or C(R₁₃), X₂₁ is N or C(R₂₁), X₂₂ is N or C(R₂₂), X₂₃ is N or C(R₂₃), X₃₁ is N or C(R₃₁), X₃₂ is N or C(R₃₂), X₃₃ is N or C(R₃₃), X₄₁ is N or C(R₄₁), X₄₂ is N or C(R₄₂), X₄₃ is N or C(R₄₃), and X₄₄ is N or C(R₄₄),

R₁₁ to R₁₃ are each independently the same as described in connection with R₁ in claim 1, and two of R₁₁ to R₁₃ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

R₂₁ to R₂₃ are each independently the same as described in connection with R₂ in claim 1, and two of R₂₁ to R₂₃ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

R₃₁ to R₃₃ are each independently the same as described in connection with R₃ in claim 1, and two of R₃₁ to R₃₃ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

R₄₁ to R₄₄ are each independently the same as described in connection with R₄ in claim 1, and two of R₄₁ to R₄₄ are optionally linked to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

two of R₁₁ to R₁₃, R₂₁ to R₂₃, R₃₁ to R₃₃, and R₄₁ to R₄₄ are optionally linked to form a substituted or unsubstituted

156

tuted C₆-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

R₆₁ and R₇₁ are each independently the same as described in connection with R₁ in claim 1,

a₆₁ and a₇₁ are each independently 0, 1, 2, or 3,



T₄ is C or Si,

T₅ is selected from a single bond, *—O—*, *—S—*, *—C(R₇)(R₈)—*, *—C(R₇)=*, *—C(R₈)=*, *—C(R₇)=C(R₈)—*, *—C(=O)—*, *—C(=S)—*, *—C≡C—*, *—N(R₇)—*, *—Si(R₇)(R₈)—*, and *—P(R₇)(R₈)—*,

R₇ and R₈ are each independently the same as described in connection with R₅ in claim 1, and


* and *' each indicate a binding site to a neighboring atom.

15. The organometallic compound of claim 1, wherein the organometallic compound is one of Compounds 1 to 132:



157

-continued



3

5


10

15

20

158

-continued



6

25



4

30

35

40

45



7



5

50

55

60


65



8

159

-continued



9

5


10

15

20

160

-continued




12

10

25

13




30

35

40

45



11



50

55

60




65

14







161

-continued




**162**

-continued



163

-continued



164

-continued

22

25

5

10

15

20

23

25

30

35

40

45



26

24 50


55

60

65



165
-continued



27

5

10

15

20

25

30

35

40

28


45

50


55

60

65




166
-continued






29

30



167

-continued



168

-continued

31

34

5

10

15

20

25

32

35

30

35

40

45

33




36

50

55




60

65



169

-continued



170

-continued

37


40

5

10

15

20



38 25


41

30

35

40

45



39


42

50

55




60

65



171

-continued

**172**

-continued

43

5

10

15

20

44

25

30

35

40

45

45

50

55




60

65

46




47

48



173

-continued

**174**

-continued

49

52

5

10

15

20

50

25

30

35

40

51

45




54

50

55




60

65






175

-continued




**176**

-continued



177

-continued

**178**

-continued


61

5

10

15

20



64


62

25

30

35

40



65

63


45

50

55




60

65



66

179
-continued



180
-continued

67


70

5

10

15

20



68


71

25

30

35

40



45
69


72

50

55


60

65



181

-continued



73

5

10

15

20

74


25

30

35

40

75 45



50


55

60


65

182


-continued



76




77



78

183

-continued



79

5


10

15

20

184


-continued



82

25

80




30

35

40

45

81




50

55

60

65




83

84

185

-continued



85

5


10

15

20


186

-continued




88

86 25



89




30

35


40

45

87



90



50

55


60

65

187

-continued

91




5

10

15

20

92 25




30

35

40

45

93



50

55


60

65


188

-continued

94






95



189

-continued



96

5

10

15

20

25

97

30

35

40

45

98

50




55

60

65

190

-continued






99

100

101

191

-continued

**192**

-continued

102

105

5

10

15

20

25

103

30

35

40

45




104

50

55




60

65



193

-continued



194

-continued

108

111

5

10

15

20

109

25

30

35

40

45




110

50

55

60

65






112

113

195

-continued



114

5

10

15

20

25

115

30

35

40

45

116

50




55

60

65

196

-continued






117

118

119

197
-continued



198
-continued

120

5

10

15

20

25

121

35

40

45

50




122

55

60

65

123







124




125

199

-continued

**200**

-continued

**16.** An organic light-emitting device comprising:

a first electrode;

a second electrode; and

an organic layer disposed between the first electrode and the second electrode, wherein the organic layer comprising an emission layer,

wherein the organic layer comprises at least one organo-metallic compound of claim 1.

17. The organic light-emitting device of claim 16, wherein the first electrode is an anode,

the second electrode is a cathode,

the organic layer further comprises a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode,

the hole transport region comprises a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and

201

the electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

18. The organic light-emitting device of claim **16**, wherein the emission layer comprises the organometallic compound. 5

19. The organic light-emitting device of claim **18**, wherein the emission layer further comprises a host, and an amount of the host is larger than an amount of the organometallic compound. 10

20. A diagnosis composition comprising at least one organometallic compound of claim **1**.

* * * * *

202

专利名称(译)	有机金属化合物，包括该有机金属化合物的有机发光器件以及包括该有机金属化合物的诊断组合物		
公开(公告)号	US10566566	公开(公告)日	2020-02-18
申请号	US15/487820	申请日	2017-04-14
[标]申请(专利权)人(译)	三星电子株式会社		
申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
当前申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
[标]发明人	JEON ARAM BAIK CHUL LEE JUNGIN CHO HWAYOUNG HONG SEOKHWAN HWANG KYUYOUNG KWON OHYUN KWAK YOONHYUN		
发明人	JEON, ARAM BAIK, CHUL LEE, JUNGIN CHO, HWAYOUNG HONG, SEOKHWAN HWANG, KYUYOUNG KWON, OHYUN KWAK, YOONHYUN		
IPC分类号	H01L51/50 H01L51/00 C09K11/06 C09K11/02 C07F15/00 H01L51/52		
CPC分类号	C09K11/025 H01L51/0094 H01L51/5203 C09K11/06 H01L51/0072 H01L51/0087 C07F15/0086 C09K2211/185 H01L51/5072 H01L51/5056 C09K2211/1014 H01L51/5096 C09K2211/1007 H01L51/5016 C09K2211/1011 C09K2211/1029 H01L51/5092 H01L51/5088 C09K2211/1022		
代理机构(译)	康托科尔伯恩LLP		
审查员(译)	CLARK , GREGORYð		
优先权	1020160124238 2016-09-27 KR		
其他公开文献	US20180090707A1		
外部链接	Espacenet		

摘要(译)

式1表示的有机金属化合物：其中，在式1中，组和变量与规范中描述的相同。

